Current Treatment Options in Oncology

, Volume 6, Issue 3, pp 255–266 | Cite as

Treatment of castleman’s disease

  • Angela Dispenzieri
  • Morie A. Gertz

Opinion statement

Castleman’s disease (CD) was first described in 1954 and further defined in 1956 by Castleman. Since then much has been learned about the heterogeneity of this condition. Subsequently, three pathologic classifications have been developed (hyaline vascular [HV] variant, plasma cell [PC] variant, and mixed variant) and two clinical classifications (unicentric [unifocal or localized] and multicentric [multifocal or generalized]). The pathology found with the unicentric presentation is most commonly that of the HV variant. It responds well to surgical resection and is associated with a benign course. The multicentric presentation is rarely composed of lymph nodes with HV pathology, but rather with the plasma cell or mixed pathology. This presentation requires systemic therapy and prognosis is guarded. Associated systemic symptoms are common. There is an increased incidence of CD in patients with HIV. The human herpes virus-8 is associated with nearly all of the HIV-associated CD cases and nearly 50% of non-HIV cases. Interleukin (IL)-6 has also been shown to play a significant role in the pathogenesis of the disease. Paraneoplastic and autoimmune entities are not uncommon in the disorder. Variable benefit has been achieved with single agent chemotherapy, combination chemotherapy, interferon (IFN)-α, rituximab, antiIL-6 receptor antibodies, and thalidomide. Patients with CD are at increased risk for developing frank malignant lymphoma.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Castleman B, Iverson L, Menendez VP: Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 1956, 9:822–830. Original description of unicentric hyaline vascular Castleman’s disease.PubMedCrossRefGoogle Scholar
  2. 2.
    Frizzera G: Castleman’s disease and related disorders. Semin Diagn Pathol 1988, 5:346–364.PubMedGoogle Scholar
  3. 3.
    Keller AR, Hochholzer L, Castleman B: Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972, 29:670–683. Distinction between hyaline vascular and plasma cell variants of Castleman’s disease.PubMedCrossRefGoogle Scholar
  4. 4.
    Gaba AR, Stein RS, Sweet DL, et al.: Multicentric giant lymph node hyperplasia. Am J Clin Pathol 1978, 69:86–90. Description of multicentric Castleman’s disease.PubMedGoogle Scholar
  5. 5.
    Parez N, Bader-Meunier B, Roy CC, et al.: Paediatric Castleman’s disease: report of seven cases and review of the literature. Eur J Pediatr 1999, 158:631–637.PubMedCrossRefGoogle Scholar
  6. 6.
    Frizzera G, Banks PM, Massarelli G, et al.: A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease. Pathological findings in 15 patients. Am J Surg Pathol 1983, 7:211–231. Review of multicentric Castleman’s disease.PubMedCrossRefGoogle Scholar
  7. 7.
    Menke DM, Camoriano JK, Banks PM: Angiofollicular lymph node hyperplasia: a comparison of unicentric, multicentric, hyaline vascular, and plasma cell types of disease by morphometric and clinical analysis. Mod Pathol 1992, 5:525–530.PubMedGoogle Scholar
  8. 8.
    Gili A, Ngan BY, Lester R: Castleman’s disease associated with pemphigus vulgaris. J Am Acad Dermatol 1991, 25:955–959.PubMedCrossRefGoogle Scholar
  9. 9.
    Wang L, Bu D, Yang Y, et al.: Castleman’s tumours and production of autoantibody in paraneoplastic pemphigus. Lancet 2004, 363:525–531.PubMedCrossRefGoogle Scholar
  10. 10.
    Strohal R, Tschachler E, Breyer S, et al.: Reactivation of Behcet’s disease in the course of multicentric HHV8-positive Castleman’s disease: long-term complete remission by a combined chemo/radiation and interferonalpha therapy regimen. Br J Haematol 1998, 103:788–790.PubMedCrossRefGoogle Scholar
  11. 11.
    Franco V, Aragona F, Rodolico V, et al.: Castleman’s disease associated with hepatic amyloidosis. An immunohistochemical and ultrastructural study. Haematologica 1984, 69:556–567.PubMedGoogle Scholar
  12. 12.
    Perfetti V, Bellotti V, Maggi A, et al.: Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman’s disease. Am J Hematol 1994, 46:189–193.PubMedCrossRefGoogle Scholar
  13. 13.
    Ordi J, Grau JM, Junque A, et al.: Secondary (AA) amyloidosis associated with Castleman’s disease. Report of two cases and review of the literature. Am J Clin Pathol 1993, 100:394–397.PubMedGoogle Scholar
  14. 14.
    Johkoh T, Muller NL, Ichikado K, et al.: Intrathoracic multicentric Castleman disease: CT findings in 12 patients. Radiology 1998, 209:477–481.PubMedGoogle Scholar
  15. 15.
    Fujimoto W, Kanehiro A, Kuwamoto-Hara K, et al.:Paraneoplastic pemphigus associated with Castleman’s disease and asymptomatic bronchiolitis obliterans. Eur J Dermatol 2002, 12:355–359.PubMedGoogle Scholar
  16. 16.
    Chin AC, Stich D, White FV, et al.: Paraneoplastic pemphigus and bronchiolitis obliterans associated with a mediastinal mass: A rare case of Castleman’s disease with respiratory failure requiring lung transplantation. J Pediatri Surg 2001, 36:E22.CrossRefGoogle Scholar
  17. 17.
    Wolff H, Kunte C, Messer G, et al.: Paraneoplastic pemphigus with fatal pulmonary involvement in a woman with a mesenteric Castleman tumour. Br J Dermatol 1999, 140:313–316.PubMedCrossRefGoogle Scholar
  18. 18.
    Seida A, Wada J, Morita Y, et al.: Multicentric Castleman’s disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cellderived growth factor play causative or protective roles in renal injury? Am J Kidney Dis 2004, 43:3–9.CrossRefGoogle Scholar
  19. 19.
    Miadonna A, Salmaso C, Palazzi P, et al.: Fibrillary glomerulonephritis in Castleman’s disease. Leuk Lymphoma 1998, 28:429–435.PubMedGoogle Scholar
  20. 20.
    Lui SL, Chan KW, Li FK, et al.: Castleman’s disease and mesangial proliferative glomerulonephritis: the role of interleukin-6. Nephron 1998, 78:323–327.PubMedCrossRefGoogle Scholar
  21. 21.
    Oksenhendler E, Boulanger E, Galicier L, et al.: High incidence of Kaposi sarcoma-associated herpesvirusrelated non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 2002, 99:2331–2336. Description of the high incidence of NHL in AIDS patients with Castleman’s disease.PubMedCrossRefGoogle Scholar
  22. 22.
    Larroche C, Cacoub P, Soulier J, et al.: Castleman’s disease and lymphoma: report of eight cases in HIVnegative patients and literature review. Am J Hematol 2002, 69:119–126. Large review of the association of lymphoma and Castleman’s disease (non-HIV related).PubMedCrossRefGoogle Scholar
  23. 23.
    Chan AC, Chan KW, Chan JK, et al.: Development of follicular dendritic cell sarcoma in hyaline-vascular Castleman’s disease of the nasopharynx: tracing its evolution by sequential biopsies. Histopathol 2001, 38:510–518.CrossRefGoogle Scholar
  24. 24.
    Soulier J, Grollet L, Oksenhendler E, et al.: Molecular analysis of clonality in Castleman’s disease. Blood 1995, 86:1131–1138.PubMedGoogle Scholar
  25. 25.
    Belec L, Mohamed AS, Authier FJ, et al.: Human herpesvirus 8 infection in patients with POEMS syndromeassociated multicentric Castleman’s disease. Blood 1999, 93(11):3643–3653.PubMedGoogle Scholar
  26. 26.
    Soulier J, Grollet L, Oksenhendler E, et al.: Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 1995, 86(4):1276–1280.PubMedGoogle Scholar
  27. 27.
    Leger-Ravet MB, Peuchmaur M, Devergne O, et al.:Interleukin-6 gene expression in Castleman’s disease. Blood 1991, 78(11):2923–2930.PubMedGoogle Scholar
  28. 28.
    Nishimoto N, Sasai M, Shima Y, et al.: Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000, 95:56–61. Trial using anti-IL-6R antibody in patients with Castleman’s disease.PubMedGoogle Scholar
  29. 29.
    McCarty MJ, Vukelja SJ, Banks PM, et al.: Angiofollicular lymph node hyperplasia (Castleman’s disease). Cancer Treat Rev 1995, 21:291–310.PubMedCrossRefGoogle Scholar
  30. 30.
    Frizzera G, Peterson BA, Bayrd ED, et al.: A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985, 3:1202–1216.PubMedGoogle Scholar
  31. 31.
    Chronowski GM, Ha CS, Wilder RB, et al.: Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001, 92:670–676. Review of therapies used for Castleman’s disease (non-AIDS population).PubMedCrossRefGoogle Scholar
  32. 32.
    Herrada J, Cabanillas F, Rice L, et al.: The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 1998, 128:657–662. Review of therapies used for Castleman’s disease.PubMedGoogle Scholar
  33. 33.
    Kasantikul V, Panyavoravut V, Benjavongkulchai S, et al.:Castleman’s disease: a clinicopathologic study of 12 cases. J Med Assoc Thai 1997, 80:195–201.PubMedGoogle Scholar
  34. 34.
    Smir BN, Greiner TC, Weisenburger DD: Multicentric angiofollicular lymph node hyperplasia in children: a clinicopathologic study of eight patients. Mod Pathol 1996, 9:1135–1142.PubMedGoogle Scholar
  35. 35.
    Oksenhendler E, Duarte M, Soulier J, et al.: Multicentric Castleman’s disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 1996, 10:61–67. Review of therapies used for Castleman’s disease (AIDS population).PubMedCrossRefGoogle Scholar
  36. 36.
    Weisenburger DD, Nathwani BN, Winberg CD, et al.:Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol 1985, 16:162–172. Review of therapies used for Castleman’s disease (non-AIDS population).PubMedCrossRefGoogle Scholar
  37. 37.
    Loi S, Goldstein D, Clezy K, et al.: Castleman’s disease and HIV infection in Australia. HIV Medicine 2004, 5:157–162.PubMedCrossRefGoogle Scholar
  38. 38.
    Safford SD, Lagoo AS, Mahaffey SA: Preoperative embolization as an adjunct to the operative management of mediastinal Castleman disease. J Pediatr Surg 2003, 38:21–23.CrossRefGoogle Scholar
  39. 39.
    Barbounis V, Efremidis A: A plasma cell variant of Castleman’s disease treated successfully with cimetidine. Case report and review of the literature. Anticancer Res 1996, 16:545–547.PubMedGoogle Scholar
  40. 40.
    Repetto L, Jaiprakash MP, Selby PJ, et al.: Aggressive angiofollicular lymph node hyperplasia (Castleman’s disease) treated with high-dose melphalan and autologous bone marrow transplantation. Hematol Oncol 1986, 4:213–217.PubMedCrossRefGoogle Scholar
  41. 41.
    Dispenzieri A, Moreno-Aspitia A, Suarez GA, et al.:Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood 2004, 104:3400–3407.PubMedCrossRefGoogle Scholar
  42. 42.
    Advani R, Warnke R, Rosenberg S: Treatment of multicentric Castleman’s disease complicated by the development of non-Hodgkin’s lymphoma with high-dose chemotherapy and autologous peripheral stem-cell support. Ann Oncol 1999, 10:1207–1209.PubMedCrossRefGoogle Scholar
  43. 43.
    Pavlidis NA, Skopouli FN, Bai MC, et al.: A successfully treated case of multicentric angiofollicular hyperplasia with oral chemotherapy (Castleman’s disease). Med Pediatr Oncol 1990, 18:333–335.PubMedCrossRefGoogle Scholar
  44. 44.
    Hudnall SD, Chen T, Brown K, et al.: Human herpesvirus-8-positive microvenular hemangioma in POEMS syndrome. Arch Pathol Lab Med 2003, 127:1034–1036.PubMedGoogle Scholar
  45. 45.
    Abdou S, Salib H: An extra ordinary respone of Castleman’s disease to rituximab. Blood 2004, 104:49b.Google Scholar
  46. 46.
    Corbellino M, Bestetti G, Scalamogna C, et al.: Longterm remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 2001, 98:3473–3475.PubMedCrossRefGoogle Scholar
  47. 47.
    Marcelin AG, Aaron L, Mateus C, et al.: Rituximab therapy for HIV-associated Castleman disease. Blood 2003, 102:2786–2788.PubMedCrossRefGoogle Scholar
  48. 48.
    Marietta M, Pozzi S, Luppi M, et al.: Acquired haemophilia in HIV-negative, HHV-8-positive multicentric Castleman’s disease: a case report. Eur J Haematol 2003, 70:181–182.PubMedCrossRefGoogle Scholar
  49. 49.
    Lee FC, Merchant SH: Alleviation of systemic manifestations of multicentric Castleman’s disease by thalidomide. Am J Hematol 2003, 73:48–53.PubMedCrossRefGoogle Scholar
  50. 50.
    Jung CP, Emmerich B, Goebel FD, et al.: Successful treatment of a patient with HIV-associated multicentric Castleman’s disease (MCD) with thalidomide. Am J Hematol 2004, 75:176–177.PubMedCrossRefGoogle Scholar
  51. 51.
    Kumari P, Schechter GP, Saini N, et al.: Successful treatment of human immunodeficiency virus-related Castleman’s disease with interferon-α. Clin Infect Dis 2000, 31:602–604.PubMedCrossRefGoogle Scholar
  52. 52.
    Nord JA, Karter D: Low-dose interferon-α therapy for HIV-associated multicentric Castleman’s disease. Int J STD AIDS 2003, 14:61–62.PubMedCrossRefGoogle Scholar
  53. 53.
    Andres E, Maloisel F: Interferon-α as first-line therapy for treatment of multicentric Castleman’s disease. Ann Oncol 2000, 11:1613–1614.PubMedCrossRefGoogle Scholar
  54. 54.
    Pavlidis NA, Briassoulis E, Klouvas G, et al.: Is interferon-α an active agent in Castleman’s disease? Ann Oncol 1992, 3:85–86.PubMedGoogle Scholar
  55. 55.
    Tamayo M, Gonzalez C, Majado MJ, et al.: Long-term complete remission after interferon treatment in a case of multicentric Castelman’s disease. Am J Hematol 1995, 49:359–360.PubMedCrossRefGoogle Scholar
  56. 56.
    Colleoni GW, Duarte LC, Kerbauy FR, et al.: 2-Chloro-deoxyadenosine induces durable complete remission in Castleman’s disease but may accelerate its transformation to non-Hodgkin’s lymphoma. Acta Oncol 2003, 42:784–787.PubMedCrossRefGoogle Scholar
  57. 57.
    Bordeleau L, Bredeson C, Markman S: 2-Chloro-deoxyadenosine therapy for giant lymph node hyperplasia. Br J Haematol 1995, 91:668–670.PubMedGoogle Scholar
  58. 58.
    Scott D, Cabral L, Harrington WJ, Jr.: Treatment of HIVassociated multicentric Castleman’s disease with oral etoposide. Am J Hematol 2001, 66:148–150.PubMedCrossRefGoogle Scholar
  59. 59.
    Aaron L, Lidove O, Yousry C, et al.: Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. Clin Infect Dis 2002, 35:880–882.PubMedCrossRefGoogle Scholar
  60. 60.
    Beck JT, Hsu SM, Wijdenes J, et al.: Alleviation of systemic manifestations of Castleman’s disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994, 330:602–605.PubMedCrossRefGoogle Scholar
  61. 61.
    van Rhee F, Alikhan M, Munshi N, et al.: Anti-IL6 antibody (abs)-based strategies improve the management of HIV-negative Castleman’s disease. Blood 2004, 104:897a.Google Scholar
  62. 62.
    Bowne WB, Lewis JJ, Filippa DA, et al.: The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature. Cancer 1999, 85:706–717. Review of therapies used in Castleman’s disease (non-HIV-associated).PubMedCrossRefGoogle Scholar
  63. 63.
    Caneppele S, Picart N, Bayle-Lebey P, et al.: Paraneoplastic pemphigus associated with Castleman’s tumour. Clin Exp Dermatol 2000, 25:219–221.PubMedCrossRefGoogle Scholar
  64. 64.
    Ruggieri G, Barsotti P, Coppola G, et al.: Membranous nephropathy associated with giant lymph node hyperplasia. A case report with histological and ultrastructural studies. Am J Nephrol 1990, 10:323–328.PubMedGoogle Scholar
  65. 65.
    Mandreoli M, Casanova S, Vianelli N, et al.: Remission of nephrotic syndrome due to AA amyloidosis and initiation of glomerular repair after surgical resection of localized Castleman’s disease. Nephron 2002, 90:336–340.PubMedCrossRefGoogle Scholar
  66. 66.
    Lachmann HJ, Gilbertson JA, Gillmore JD, et al.: Unicentric Castleman’s disease complicated by systemic AA amyloidosis: a curable disease. QJM 2002, 95:211–218.PubMedCrossRefGoogle Scholar
  67. 67.
    Gulati P, Sun NC, Herman BK, et al.: Isolated leptomeningeal Castleman’s disease with viral particles in the follicular dendritic cells. Arch Pathol Lab Med 1998, 122:1026–1029.PubMedGoogle Scholar
  68. 68.
    Yamasaki S, Iino T, Nakamura M, et al.: Detection of human herpesvirus-8 in peripheral blood mononuclear cells from adult Japanese patients with multicentric Castleman’s disease. Br J Haematol 2003, 120:471–477.PubMedCrossRefGoogle Scholar
  69. 69.
    Chan TM, Cheng IK, Wong KL, et al.: Resolution of membranoproliferative glomerulonephritis complicating angiofollicular lymph node hyperplasia (Castleman’s disease). Nephron 1993, 65:628–632.PubMedGoogle Scholar
  70. 70.
    Hattori K, Irie S, Isobe Y, et al.: Multicentric Castleman’s disease associated with renal amyloidosis and pure red cell aplasia. Ann Hematol 1998, 77:179–181.PubMedCrossRefGoogle Scholar
  71. 71.
    Liberato NL, Bollati P, Chiofalo F, et al.: Autoimmune hemolytic anemia in multicentric Castleman’s disease. Haematologica 1996, 81:40–43.PubMedGoogle Scholar
  72. 72.
    Higashi K, Matsuki Y, Hidaka T, et al.: Primary Sjogren’s syndrome associated with hyaline-vascular type of Castleman’s disease and autoimmune idiopathic thrombocytopenia. Scand J Rheumatol 1997, 26:482–484.PubMedCrossRefGoogle Scholar
  73. 73.
    Dispenzieri A, Kyle RA, Lacy MQ, et al.: POEMS syndrome: definitions and long-term outcome. Blood 2003, 101:2496–2506.PubMedCrossRefGoogle Scholar
  74. 74.
    Rywlin AM, Rosen L, Cabello B: Coexistence of Castleman’s disease and Kaposi’s sarcoma. Report of a case and a speculation. Am J Dermatopathol 1983, 5:277–281.PubMedCrossRefGoogle Scholar
  75. 75.
    Gerald W, Kostianovsky M, Rosai J: Development of vascular neoplasia in Castleman’s disease. Report of seven cases. Am J Surg Pathol 1990, 14:603–614.PubMedCrossRefGoogle Scholar
  76. 76.
    Suwannaroj S, Elkins SL, McMurray RW: Systemic lupus erythematosus and Castleman’s disease. J Rheumatol 1999, 26:1400–1403.PubMedGoogle Scholar
  77. 77.
    Massey GV, Kornstein MJ, Wahl D, et al.: Angiofollicular lymph node hyperplasia (Castleman’s disease) in an adolescent female. Clinical and immunologic findings. Cancer 1991, 68:1365–1372.PubMedCrossRefGoogle Scholar
  78. 78.
    Crump JA, Beard ME, Angus HB, et al.: Acute adrenal insufficiency: a new presentation of Castleman’s disease. J Intern Med 1995, 238:81–84.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Angela Dispenzieri
    • 1
  • Morie A. Gertz
  1. 1.Division of HematologyMayo ClinicRochester

Personalised recommendations